These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23234317)

  • 1. The rise of the biosimilar.
    McCamish M; Woollett G
    Expert Rev Clin Pharmacol; 2012 Nov; 5(6):597-9. PubMed ID: 23234317
    [No Abstract]   [Full Text] [Related]  

  • 2. Biosimilars in rheumatology: the wind of change.
    Schneider CK
    Ann Rheum Dis; 2013 Mar; 72(3):315-8. PubMed ID: 23390018
    [No Abstract]   [Full Text] [Related]  

  • 3. Analytical and bioanalytical assay challenges to support comparability studies for biosimilar drug development.
    Cai XY; Wake A; Gouty D
    Bioanalysis; 2013 Mar; 5(5):517-20. PubMed ID: 23425265
    [No Abstract]   [Full Text] [Related]  

  • 4. Mini Focus: bioanalysis of biosimilars.
    Amaravadi L; Marini J
    Bioanalysis; 2013 Mar; 5(5):515-6. PubMed ID: 23425264
    [No Abstract]   [Full Text] [Related]  

  • 5. European perspective on biosimilars.
    Wadhwa M; Thorpe R
    Bioanalysis; 2013 Mar; 5(5):521-4. PubMed ID: 23425266
    [No Abstract]   [Full Text] [Related]  

  • 6. Insights of biosimilars through SWOT analysis.
    Patel MM; Shah PJ; Patel BM
    Expert Opin Biol Ther; 2014 Feb; 14(2):139-44. PubMed ID: 24151903
    [No Abstract]   [Full Text] [Related]  

  • 7. The use of pharmacometrics to optimize biosimilar development.
    Dodds M; Chow V; Markus R; Pérez-Ruixo JJ; Shen D; Gibbs M
    J Pharm Sci; 2013 Nov; 102(11):3908-14. PubMed ID: 24027111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Controversy on biosimilar drugs and their therapeutic exchange].
    Dorantes Calderón B
    Farm Hosp; 2009; 33(4):181-2. PubMed ID: 19712605
    [No Abstract]   [Full Text] [Related]  

  • 9. Biosimilars.
    Malozowski S
    Arq Bras Endocrinol Metabol; 2011 Nov; 55(8):669. PubMed ID: 22218453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilars: the 'future' of biologic therapy?
    Ranjan N; Mahajan VK; Misra M
    J Dermatolog Treat; 2011 Dec; 22(6):319-22. PubMed ID: 20666673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using Clinical PK/PD Studies to Support No Clinically Meaningful Differences Between a Proposed Biosimilar and the Reference Product.
    Zhu P; Ji P; Wang Y
    AAPS J; 2018 Aug; 20(5):89. PubMed ID: 30094524
    [No Abstract]   [Full Text] [Related]  

  • 12. Biosimilars and biobetters as tools for understanding and mitigating the immunogenicity of biotherapeutics.
    Barbosa MD; Kumar S; Loughrey H; Singh SK
    Drug Discov Today; 2012 Dec; 17(23-24):1282-8. PubMed ID: 22796124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biosimilar drugs – just as good, and much cheaper].
    Goll GL
    Tidsskr Nor Laegeforen; 2019 Mar; 139(6):. PubMed ID: 30917643
    [No Abstract]   [Full Text] [Related]  

  • 14. Another nail in the biosimilar coffin?
    Nat Biotechnol; 2012 Mar; 30(3):198. PubMed ID: 22398594
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of Modeling and Simulation in the Development of Novel and Biosimilar Therapeutic Proteins.
    Wang YC; Wang Y; Schrieber SJ; Earp J; Thway TM; Huang SM; Zineh I; Christl L
    J Pharm Sci; 2019 Jan; 108(1):73-77. PubMed ID: 30395832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction and commentary: Paving the way for biosimilars in oncology, part 3: Clinical and economic impact of oncology biosimilars.
    Abraham J
    Semin Oncol; 2014 Apr; 41 Suppl 3():S1-2. PubMed ID: 24767631
    [No Abstract]   [Full Text] [Related]  

  • 17. Non-inferiority versus equivalence clinical trials in assessing biological products.
    Pinto VF
    Sao Paulo Med J; 2011 May; 129(3):183-4. PubMed ID: 21755255
    [No Abstract]   [Full Text] [Related]  

  • 18. Analytical and Biological Characterization of a Noninnovator Insulin Glargine and the Originator Drug Product.
    Escobedo-Moratilla A; Kuri-Breña Romero de Terreros F; Pérez-Urizar J; Barba de la Rosa AP
    J Diabetes Sci Technol; 2015 Oct; 10(2):616-7. PubMed ID: 26428936
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug companies lobby against generic versions of biologics.
    Tucker ME
    BMJ; 2013 Feb; 346():f740. PubMed ID: 23381589
    [No Abstract]   [Full Text] [Related]  

  • 20. [Mexico recovers leadership on regulation of biosimilar biotech drugs].
    López Silva C
    Gac Med Mex; 2012; 148(1):83-90. PubMed ID: 22367313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.